Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
1. A method for the treatment of cancer, comprising the concurrent administration to a mammal in need thereof a synergistic, therapeutically effective amount of an anti-CTLA-4 antibody with 2′-deoxy-2′,2′-difluorocytidine monohydrochloride (β-isomer), or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
2. The method according to claim 1 , wherein the anti-CTLA-4 antibody is selected from the group consisting of: ipilimumab and tremelimumab.
3. The method according to claim 1 , wherein said anti-CTLA-4 antibody is ipilimumab.
4. The method according to claim 1 , wherein said cancer is a solid tumor.
5. The method according to claim 4 , wherein said solid tumor is selected from the group consisting of: lung carcinoma, lung metastasis, and colon carcinoma.
6. The method according to claim 1 , wherein said method is for the treatment of a tumor refractory to said monohydrochloride.
7. The method according to claim 1 , wherein said monohydrochloride is administered essentially simultaneously with the administration of said anti-CTLA4 antibody.
8. The method according to claim 1 , wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy.
9. The method according to claim 8 , wherein said anti-proliferative cytotoxic agent is cisplatin.
10. The method according to claim 8 , wherein said anti-proliferative cytotoxic agent is paraplatin.
11. The method according to claim 1 , wherein said monohydrochloride is administered at a dose of about 200 mg.
12. The method according to claim 1 , wherein said monohydrochloride is administered at a dose of about 1 g.
13. The method according to claim 1 , wherein said monohydrochloride is administered via IV infusion.
14. The method according to claim 1 , wherein said anti-CTLA4 antibody is administered about every three weeks.
15. The method according to claim 4 , wherein said solid tumor is lung carcinoma.
16. The method according to claim 4 , wherein said solid tumor is lung metastasis.
17. The method according to claim 4 , wherein said solid tumor is colon carcinoma.